Jupiter Asset Management Ltd. Lowers Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Jupiter Asset Management Ltd. lessened its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 9.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 319,446 shares of the biotechnology company’s stock after selling 32,531 shares during the period. Jupiter Asset Management Ltd. owned approximately 1.18% of Arcturus Therapeutics worth $5,421,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Arcturus Therapeutics by 10.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock valued at $202,000 after acquiring an additional 846 shares during the period. SG Americas Securities LLC grew its position in Arcturus Therapeutics by 45.0% during the fourth quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock valued at $203,000 after acquiring an additional 3,705 shares during the period. Spire Wealth Management boosted its position in shares of Arcturus Therapeutics by 393.3% in the fourth quarter. Spire Wealth Management now owns 13,478 shares of the biotechnology company’s stock worth $229,000 after buying an additional 10,746 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Arcturus Therapeutics by 954.7% in the third quarter. BNP Paribas Financial Markets now owns 15,831 shares of the biotechnology company’s stock worth $367,000 after buying an additional 14,330 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in shares of Arcturus Therapeutics in the third quarter worth about $420,000. Hedge funds and other institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Stock Performance

Shares of ARCT opened at $13.90 on Friday. The company has a market capitalization of $376.97 million, a P/E ratio of -6.26 and a beta of 2.96. Arcturus Therapeutics Holdings Inc. has a one year low of $12.75 and a one year high of $45.00. The stock has a 50-day moving average price of $16.72 and a 200 day moving average price of $18.38.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The firm had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. As a group, equities research analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ARCT has been the subject of several analyst reports. BTIG Research set a $48.00 target price on Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday. HC Wainwright decreased their target price on Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a research report on Friday, March 7th. Canaccord Genuity Group decreased their target price on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, Wells Fargo & Company decreased their target price on Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Arcturus Therapeutics presently has an average rating of “Buy” and a consensus target price of $59.20.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.